Article
Become a Member to Save

Product Information

Adverse event reporting information can be found at the bottom of this page.

LIVTENCITY®▼(Maribavir): Now approved in the UK for post-transplant adult patients with refractory CMV infection and/or disease.1

CMV infection during post-transplant recovery puts patients at risk of graft rejection, increased hospitalisations, opportunistic infections, and mortality2–6. Furthermore, management of persistent CMV infection can lead to resistance, graft rejection, neutropenia, and nephrotoxicity, while rates of drug resistance vary and can occur in up to 8% of HSCT recipients and in up to 31% of SOT recipients2,7–9.


Summary of Product Characteristics & Relevant Guidance

LIVTENCITY 200 mg film coated tablets


LIVTENCITY is the first and only therapy indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT)1,5.

LIVTENCITY: REDEFINING POST-TRANSPLANT TREATMENT FOR REFRACTORY CMV INFECTION1

  • OFFERS A TREATMENT OPTION FOR POST-TRANSPLANT ADULT PATIENTS WHO BECOME REFRACTORY TO ANTI-CMV THERAPIES
  • TWICE-DAILY, ORAL ADMINISTRATION, WITH OR WITHOUT FOOD1
  • MULTIMODAL MECHANISM OF ACTION THAT INHIBITS THE CMV-SPECIFIC UL97 PROTEIN KINASE1,7,10

The Phase 3 SOLSTICE study

A summary of the efficacy outcomes and safety profile for LIVTENCITY in the Phase 3 SOLSTICE study can be found in the LIVTENCITY digital key facts booklet


Book a meeting

To find out more about how LIVTENCITY could benefit your SOT or HSCT adult patients with refractory CMV infection, book a meeting with your local Takeda representative.

Contact Us


Adverse Events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store.
Adverse Events should be reported to Takeda by email at AE.GBR-IRL@takeda.com

REFERENCES:

  1. LIVTENCITY UK Summaries of Product Characteristics [GB & NI].
  2. Felipe CR, et al. J Bras Nefrol. 2017;39:413–23.
  3. Azevedo LS, et al. Clinics (Sau Paulo). 2015;70:515–23.
  4. Peffault De Latour R, et al. J Med Virol. 2020;92:3665–73.
  5. Henderson R, et al. Transp! Infect Dis. 2001;3(suppl. 2):57–9.
  6. Schelfhout J, et al. Curr Med Res Opin. 2020;36:43–50.
  7. Kotton CN, et al. Transplantation. 2018;102:900–31.
  8. Maffini E, et al. Expert Rev Hematol. 2016;9:588–96.
  9. Razonable RR, et al. Am J Transplant. 2013;13(suppl. 4):93–106.
  10. Avery RK, et al. Clin Infect Dis 2022;75(4):690–701.
Cytomegalovirus
Allied Professional
CMT
Consultant
FY1/FY2
General Practitioner
Nurse
Specialist Nurse
ST3+
Post-transplant (HSCT / SOT)
Disease Awareness
Contribute

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

Adverse events should also be reported to Takeda UK Ltd. at: AE.GBR-IRL@takeda.com

Rare Disease Hub is for UK healthcare professionals only. This website has been initiated and developed by Takeda.

Copyright © 2023 Takeda UK Ltd.

 

C-APROM/GB/CMV/0001

April 2023